Literature DB >> 33103785

Nonparametric Methods in Population Pharmacokinetics.

Sylvain Goutelle1,2,3, Jean-Baptiste Woillard4,5,6, Michael Neely7,8, Walter Yamada7, Laurent Bourguignon1,2,3.   

Abstract

Population pharmacokinetic (PK) modeling is a widely used approach to analyze PK data obtained from groups of individuals, in both industry and academic research. The approach can also be used to analyze pharmacodynamic (PD) data and pooled PK/PD data. There are 2 main families of population PK methods: parametric and nonparametric. The objectives of this article are to present an overview of nonparametric methods used in population pharmacokinetic modeling and to explain their specific characteristics to inform scientists and clinicians about their potential value for data analysis, simulation, dosage design, and therapeutic drug monitoring (TDM). Nonparametric methods have several interesting characteristics for population PK analysis, including computation of exact likelihoods, the ability to accommodate parameter probability distributions of any shape (eg, non-Gaussian), and to detect subpopulations and outliers. Nonparametric population methods are also highly relevant for model-based TDM and design of individualized drug dosage regimens. Several algorithms have been developed to estimate model parameter values within an individual and compute that individual's dosage to achieve target drug exposure with maximum precision and accuracy. Nonparametric modeling methods for both population and individual PK analysis are available under user-friendly packages.
© 2020, The American College of Clinical Pharmacology.

Entities:  

Keywords:  data analysis; nonparametric statistics; pharmacodynamics; pharmacokinetics; population pharmacokinetics

Mesh:

Substances:

Year:  2020        PMID: 33103785     DOI: 10.1002/jcph.1650

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  5 in total

1.  Population Pharmacokinetics and Dosing Regimen Optimization of Latamoxef in Chinese Children.

Authors:  Yang Wang; Dan Sun; Yan Mei; Sanlan Wu; Xinlin Li; Sichan Li; Jun Wang; Liuliu Gao; Hua Xu; Yali Tuo
Journal:  Pharmaceutics       Date:  2022-05-11       Impact factor: 6.525

2.  Applying Cefepime Population Pharmacokinetics to Critically Ill Patients Receiving Continuous Renal Replacement Therapy.

Authors:  Mohammad H Al-Shaer; Kelly Maguigan; Jennifer Ashton; Veena Venugopalan; Molly E Droege; Carolyn D Philpott; Christopher A Droege; Daniel P Healy; Eric W Mueller; Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2021-10-18       Impact factor: 5.938

3.  Implementation of Model-Based Dose Adjustment of Tobramycin in Adult Patients with Cystic Fibrosis.

Authors:  Jérémy Reverchon; Vianney Tuloup; Romain Garreau; Viviane Nave; Sabine Cohen; Philippe Reix; Stéphane Durupt; Raphaele Nove-Josserand; Isabelle Durieu; Quitterie Reynaud; Laurent Bourguignon; Sandrine Charles; Sylvain Goutelle
Journal:  Pharmaceutics       Date:  2022-08-22       Impact factor: 6.525

4.  A High-Throughput Clinical Laboratory Methodology for the Therapeutic Monitoring of Ibrutinib and Dihydrodiol Ibrutinib.

Authors:  Gellért Balázs Karvaly; István Vincze; Alexandra Balogh; Zoltán Köllő; Csaba Bödör; Barna Vásárhelyi
Journal:  Molecules       Date:  2022-07-25       Impact factor: 4.927

5.  Implementation and Comparison of Two Pharmacometric Tools for Model-Based Therapeutic Drug Monitoring and Precision Dosing of Daptomycin.

Authors:  Justine Heitzmann; Yann Thoma; Romain Bricca; Marie-Claude Gagnieu; Vincent Leclerc; Sandrine Roux; Anne Conrad; Tristan Ferry; Sylvain Goutelle
Journal:  Pharmaceutics       Date:  2022-01-04       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.